ClinicalTrials.gg
CompletedNCT03682770Updated Feb 7, 2024Results posted

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

A Phase 2 interventional study of Dupilumab and Placebo matching dupilumab in Peanut Allergy, sponsored by Regeneron Pharmaceuticals. Completed at 25 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies in Peanut Hypersensitivity with a site in United States — 10 open to participants now, 16 under way, 3 of them phase 3. Peanut Hypersensitivity · United States.

Enrollment
21st of 87
148 · median 47
Started
2018
with 3 others
Phase 2
26 of 99
3 open now
Registered
60th of 99
by date

Among the 99 studies in Peanut Hypersensitivity with a site in United States, this one is the 21st largest by enrollment of the 87 interventional ones that give a count, is one of 4 that started in 2018, is one of 26 in phase 2, and was the 60th registered.

Peanut Hypersensitivity

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

Browse Peanut Hypersensitivity studies →

Open to participants now

10 of the 99 studies in Peanut Hypersensitivity with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies in Peanut Hypersensitivity with a site in United States, or all of them as a file.
02

Study summary

Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing double-blind placebo-controlled food challenge (DBPCFC) at visit 16.

Secondary objectives are:

  • To assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the cumulative tolerated dose (log transformed) of peanut protein during a post up-dosing DBPCFC at visit 16
  • To assess whether dupilumab as (indefinite [continuously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
  • To assess whether dupilumab as (limited [previously]) adjunct to AR101 compared to placebo maintains desensitization, defined as an increase in the proportion of participants who pass a post maintenance DBPCFC at visit 22
  • To evaluate the safety and tolerability of dupilumab as adjunct to AR101 compared to placebo
  • To assess the effect of dupilumab (compared to placebo) as adjunct to AR101 on the change in peanut-specific Immunoglobulin E (sIgE), Immunoglobulin G (IgG), Immunoglobulin G4 (IgG4), and peanut-specific IgG4/IgE ratio
  • To assess if dupilumab increases the tolerability of AR101 as measured by the daily symptoms (electronic diary [e-diary]) during the up-dosing phase
03

Conditions studied

  • Peanut Allergy
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening and not experiencing dose-limiting symptoms to placebo as defined in the protocol
  • Serum Immunoglobulin E (IgE) to peanut of ≥10 kUA/L and/or a skin prick test (SPT) to peanut ≥8 mm compared to a negative control
  • Participants/legal guardians must be trained on the proper use of the epinephrine autoinjector device to be allowed to enroll in the study
  • Participants with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study

Key Exclusion Criteria:

  • History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or allergic rhinitis) requiring therapy (eg, heart disease, diabetes, hypertension) that would represent a risk to participant's health or safety in this study or ability to comply with study protocol
  • History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock
  • History of eosinophilic Gastrointestinal (GI) disease
  • Asthma at time of enrollment with any of the following:

    • Forced Expiratory Volume 1 Second () \<80% of predicted or ratio of FEV1 to forced vital capacity (FEV1/FVC) \<75% of predicted with or without controller medications
    • Inhaled (ICS) dosing of daily fluticasone (or equivalent ICS based on NHLBI dosing chart)
    • One hospitalization in the past year for asthma
    • Emergency room visit for asthma within 6 months prior to screening
  • Use of systemic corticosteroids within 2 months prior to screening
  • Use of other forms of allergen immunotherapy or immunomodulatory therapy within 3 months prior to screening
  • Use of any agents known or likely to interact with epinephrine (eg, beta-blockers, angiotensin converting enzyme-inhibitors, tri-cyclic antidepressants, or other drugs), within 3 weeks prior to screening
  • Allergy to oat (placebo in DBPCFC)

Note: Other protocol Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    dupilumab + AR101

    Participant randomization of a ratio of 2 active dupilumab arms

    Drug: Dupilumab · Drug: AR101

  • Experimental
    placebo matching dupilumab + AR101

    Participant randomization of a ratio of 1 placebo arm

    Drug: Placebo matching dupilumab · Drug: AR101

Interventions

  • Dupilumab will be administered subcutaneously (SC) in a single-use, pre-filled glass syringe every two weeks (Q2W)

  • DrugPlacebo matching dupilumab

    Placebo matching dupilumab is prepared in the same formulation without the addition of protein

  • DrugAR101

    Drug pages: Panobacumab · Iclaprim, (r)-

    AR101 will be provided in dose-escalating capsules and then sachets during maintenance phase

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40)

    Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post up-dosing DBPCFC with 2044 mg (Cumulative) peanut protein at Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).

    Time frame: At Visit 16 (Week 28 to 40)

Secondary outcomes

  1. Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 16 (Week 28 to 40) in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101

    Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 16 (Week 28 to 40) in participants treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 28 to Week 40).

    Time frame: Baseline, Visit 16 (Week 28 to 40)

  2. Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Reached the 300 mg/Day Dose of AR101 by Visit 16 (Week 28 to 40)

    Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who reached the 300 mg/day dose of AR101 by Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).

    Time frame: At Visit 16 (Week 28 to 40)

  3. Time From Randomization to the First Time When Participants Reached the 300 mg/Day Dose of AR101 During the Up-dosing Treatment Phase by Visit 16 (Week 28 to 40)

    Time (in days) from randomization to the first time when participants reached the 300 mg/day dose of AR101 during the up-dosing treatment phase by Visit 16 (Week 28 to 40) was reported. If participants did not reach the 300 mg/day dose of AR101 during the 28-week treatment period, they were censored at the date of their last visit during pre-AR101 dosing and AR101 up-dosing treatment period. Analysis was performed using Kaplan-Meier Estimated method.

    Time frame: At Visit 16 (Week 28 to 40)

  4. Percentage of Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)

    Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).

    Time frame: At Visit 22 (Week 52 to 64)

  5. Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101

    Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).

    Time frame: Baseline, Visit 22 (Week 52 to 64)

  6. Percentage of Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)

    Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 who "pass" a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).

    Time frame: At Visit 22 (Week 52 to 64)

  7. Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101

    Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).

    Time frame: Baseline, Visit 22 (Week 52 to 64)

  8. Percent Change From Baseline in Peanut-specific IgE in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 16 (Week 28 to 40)

    Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 16 (Week 28 to 40) was reported. Analysis was performed using Last observation carried forward (LOCF) method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).

    Time frame: Baseline up to Visit 16 (Weeks 28 to 40)

  9. Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 22 (Week 52 to 64)

    Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 22 (Week 52 to 64) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).

    Time frame: Baseline up to Visit 22 (Week 52 to 64)

  10. Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 25 (Weeks 64 to 76)

    Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 25 (Week 64 to 76) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 64 to Week 76).

    Time frame: Baseline up to Visit 25 (Weeks 64 to 76)

07

Results

Posted Feb 7, 2024

Participant flow

Pre-AR101 Dosing Period (Day 1 - Week 4)
Participant flow — Pre-AR101 Dosing Period (Day 1 - Week 4)
MilestonePre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101
Started509800000
Completed499600000
Not completed1200000
Withdrew: Sponsor decision0100000
Withdrew: Withdrawal by subject1100000
AR101 Up-dosing Period (Week 28-40)
Participant flow — AR101 Up-dosing Period (Week 28-40)
MilestonePre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101
Started004996000
Completed003988000
Not completed00108000
Withdrew: Withdrawal by subject0073000
Withdrew: Protocol violation0001000
Withdrew: Investigator/sponsor decision0012000
Withdrew: Adverse event0010000
Withdrew: Chronic/recurrent gi aes/symptoms0010000
Withdrew: Other0002000
AR101 Maintenance Period: (Week 52-64)
Participant flow — AR101 Maintenance Period: (Week 52-64)
MilestonePre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101
Started0000404444
Randomized and treated0000404342
Completed0000364141
Not completed0000433
Withdrew: Withdrawal by subject0000311
Withdrew: Investigator/sponsor decision0000100
Withdrew: Other0000010
Withdrew: Randomized, but not treated0000012

Outcome measures

PrimaryPercentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40)

Symptoms considered to be allergic were graded using the Consortium of Food Allergy Research (CoFAR) Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post up-dosing DBPCFC with 2044 mg (Cumulative) peanut protein at Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).

Time frame:
At Visit 16 (Week 28 to 40)
Reported as:
Number · Percentage of participants
Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40)
Percentage of participantsAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101
Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Up-dosing Double-blind, Placebo-controlled Food Challenge (DBPCFC) With 2044 mg (Cumulative) Peanut Protein at Visit 16 (Week 28 to 40)35.90 (21.204 to 52.820)55.95 (44.695 to 66.778)
Statistical analysis
  • AR101 Up-dosing Period: Placebo + AR101 vs AR101 Up-dosing Period: Dupilumab + AR101 · Cochran-Mantel-Haenszel · p = 0.0420 (The p-value was derived by Cochran-Mantel-Haenszel (CMH) test stratified by screening peanut-specific IgE level and baseline body weight.) · Difference in percentage: 20.23 · 95% CI 1.266 to 39.189Difference in percentage derived by Mantel-Haenszel (MH) method
SecondaryChange From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 16 (Week 28 to 40) in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101

Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 16 (Week 28 to 40) in participants treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 28 to Week 40).

Time frame:
Baseline, Visit 16 (Week 28 to 40)
Reported as:
Least squares mean · Log Transformed Milligrams
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 16 (Week 28 to 40) in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101
Log Transformed MilligramsAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 16 (Week 28 to 40) in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR1013.78 ± 0.2704.45 ± 0.205
Statistical analysis
  • AR101 Up-dosing Period: Placebo + AR101 vs AR101 Up-dosing Period: Dupilumab + AR101 · ANCOVA · p = 0.0400 (P-value is based on treatment difference (dupilumab + AR101 vs placebo + AR101) of the LS mean change using analysis of covariance (ANCOVA) model.) · Least square mean difference: 0.67 · 95% CI 0.031 to 1.305
SecondaryPercentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Reached the 300 mg/Day Dose of AR101 by Visit 16 (Week 28 to 40)

Percentage of participants treated with dupilumab plus AR101 vs placebo plus AR101 who reached the 300 mg/day dose of AR101 by Visit 16 (Week 28 to 40) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).

Time frame:
At Visit 16 (Week 28 to 40)
Reported as:
Number · Percentage of participants
Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Reached the 300 mg/Day Dose of AR101 by Visit 16 (Week 28 to 40)
Percentage of participantsAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101
Percentage of Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Reached the 300 mg/Day Dose of AR101 by Visit 16 (Week 28 to 40)76.92 (60.674 to 88.866)89.29 (80.633 to 94.982)
Statistical analysis
  • AR101 Up-dosing Period: Placebo + AR101 vs AR101 Up-dosing Period: Dupilumab + AR101 · Cochran-Mantel-Haenszel · p = 0.0806 (P-values were derived by CMH test stratified by screening peanut-specific IgE level (\<=100 kilo allergy unit per liter \[kUA/L\] vs \>100 kUA/L) and body weight (\<30 kg, \>=30 and \<60 kg, or \>=60 kg).) · Difference in percentage: 11.91 · 95% CI -3.612 to 27.440Difference in percentage derived by MH method
SecondaryTime From Randomization to the First Time When Participants Reached the 300 mg/Day Dose of AR101 During the Up-dosing Treatment Phase by Visit 16 (Week 28 to 40)

Time (in days) from randomization to the first time when participants reached the 300 mg/day dose of AR101 during the up-dosing treatment phase by Visit 16 (Week 28 to 40) was reported. If participants did not reach the 300 mg/day dose of AR101 during the 28-week treatment period, they were censored at the date of their last visit during pre-AR101 dosing and AR101 up-dosing treatment period. Analysis was performed using Kaplan-Meier Estimated method.

Time frame:
At Visit 16 (Week 28 to 40)
Reported as:
Mean · Days
Time From Randomization to the First Time When Participants Reached the 300 mg/Day Dose of AR101 During the Up-dosing Treatment Phase by Visit 16 (Week 28 to 40)
DaysAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101
Time From Randomization to the First Time When Participants Reached the 300 mg/Day Dose of AR101 During the Up-dosing Treatment Phase by Visit 16 (Week 28 to 40)164.6 ± 38.43167.5 ± 32.01
SecondaryPercentage of Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)

Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 who passed a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).

Time frame:
At Visit 22 (Week 52 to 64)
Reported as:
Number · Percentage of participants
Percentage of Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)
Percentage of participantsAR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 Continued
Percentage of Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)47.50 (31.512 to 63.872)56.82 (41.034 to 71.651)
Statistical analysis
  • AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued vs AR101 Maintenance Period: Dupilumab + AR101 Continued · Cochran-Mantel-Haenszel · p = 0.3530 (P-values were derived by CMH test stratified by screening peanut-specific IgE level (\<=100 kUA/L vs \>100 kUA/L) and baseline body weight (\<30 kg, \>=30 kg and \<60 kg, or \>=60 kg).) · Difference in percentage: 10.40 · 95% CI -11.668 to 32.474Difference in percentage derived by MH method
SecondaryChange From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101

Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (continuously) treated with dupilumab plus AR101 vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).

Time frame:
Baseline, Visit 22 (Week 52 to 64)
Reported as:
Least squares mean · Log Transformed Milligrams
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101
Log Transformed MilligramsAR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 Continued
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR1014.19 ± 0.2454.56 ± 0.250
Statistical analysis
  • AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued vs AR101 Maintenance Period: Dupilumab + AR101 Continued · ANCOVA · p = 0.2628 (P-value is based on treatment difference of the LS mean change using ANCOVA model with baseline tolerated cumulative amount of peanut protein DBPCFC (log transformed) as covariate and the treatment screening peanut-specific IgE level and baseline.) · Least square mean difference: 0.37 · 95% CI -0.281 to 1.029
SecondaryPercentage of Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)

Symptoms considered to be allergic were graded using the CoFAR Grading Scale for Systemic Allergic Reactions. The allergic reaction is measured on a 1-5 scale, with grade 1 being mild, grade 2 being moderate, grade 3 being severe, grade 4 being life threatening, and grade 5 as death. the higher the grade, the more severe the allergic reaction. Participants were considered to have passed the DBPCFC if they did not experience any objective Grade 1 reaction. Percentage of participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 who "pass" a post maintenance DBPCFC with 2044 mg (cumulative) peanut protein at Visit 22 (Week 52 to 64) was reported. Cumulative data during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).

Time frame:
At Visit 22 (Week 52 to 64)
Reported as:
Number · Percentage of participants
Percentage of Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)
Percentage of participantsAR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101
Percentage of Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101 Who Passed a Post Maintenance DBPCFC With 2044 mg (Cumulative) Peanut Protein at Visit 22 (Week 52 to 64)47.50 (31.512 to 63.872)45.45 (30.391 to 61.153)
Statistical analysis
  • AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued vs AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 · Cochran-Mantel-Haenszel · p = 0.8140 (P-values were derived by CMH test stratified by screening peanut-specific IgE level (\<=100 kUA/L vs \>100 kUA/L) and baseline body weight (\<30 kg, \>=30 kg and \<60 kg, or \>=60 kg).) · Difference in percentage: -2.36 · 95% CI -25.004 to 20.282Difference in percentage derived by MH method
SecondaryChange From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101

Change from baseline in cumulative tolerated dose (log transformed) of peanut protein during a DBPCFC at Visit 22 (Week 52 to 64) in participants (previously) treated with dupilumab plus AR101 (and re-randomized to placebo plus AR101) vs placebo plus AR101 was reported. Cumulative tolerated dose during the specified period was calculated as the mean of all available post-randomization values during the specified time period (Week 52 to Week 64).

Time frame:
Baseline, Visit 22 (Week 52 to 64)
Reported as:
Least squares mean · Log Transformed Milligrams
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR101
Log Transformed MilligramsAR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101
Change From Baseline in Cumulative Tolerated Dose (Log Transformed) of Peanut Protein During a DBPCFC at Visit 22 (Week 52 to 64) in Participants (Previously) Treated With Dupilumab + AR101/Placebo +AR101 vs Placebo Plus AR1014.19 ± 0.2454.14 ± 0.244
Statistical analysis
  • AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued vs AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101 · ANCOVA · p = 0.8805 (P-value is based on treatment difference of the LS mean change using ANCOVA model with baseline tolerated cumulative amount of peanut protein DBPCFC (log transformed) as covariate and the treatment screening peanut-specific IgE level and baseline.) · Least square mean difference: -0.05 · 95% CI -0.699 to 0.599
SecondaryPercent Change From Baseline in Peanut-specific IgE in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 16 (Week 28 to 40)

Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 16 (Week 28 to 40) was reported. Analysis was performed using Last observation carried forward (LOCF) method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 28 to Week 40).

Time frame:
Baseline up to Visit 16 (Weeks 28 to 40)
Reported as:
Median · Percent change
Percent Change From Baseline in Peanut-specific IgE in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 16 (Week 28 to 40)
Percent changeAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101
Percent Change From Baseline in Peanut-specific IgE in Participants Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 16 (Week 28 to 40)29.9 (3.3 to 82.2)-60.6 (-68.1 to -50.5)
SecondaryPercent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 22 (Week 52 to 64)

Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 22 (Week 52 to 64) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 52 to Week 64).

Time frame:
Baseline up to Visit 22 (Week 52 to 64)
Reported as:
Median · Percent change
Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 22 (Week 52 to 64)
Percent changeAR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 Continued
Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 22 (Week 52 to 64)10.1 (-73.3 to 98.5)-73.7 (-91.7 to -52.5)
Statistical analysis
  • AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued vs AR101 Maintenance Period: Dupilumab + AR101 Continued · ANCOVA · p = <0.0001 (P-value was based on treatment difference (vs. Continuously on Placebo + AR101) in percent change from baseline using rank-based ANCOVA model with baseline measurement as covariate,- and stratification factors and the treatment as fixed factors.) · Difference percentage: -85.55 · 95% CI -99.47 to -73.91Median difference and its 95% CIs were estimated with the Hodges-Lehmann method.
SecondaryPercent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 25 (Weeks 64 to 76)

Percent change from baseline in peanut-specific IgE in participants treated with dupilumab + AR101 vs placebo + AR101 to Visit 25 (Week 64 to 76) was reported. Analysis was performed using LOCF method. Data reported during the specified period was calculated as the average of all available post-randomization values during the specified time period (Week 64 to Week 76).

Time frame:
Baseline up to Visit 25 (Weeks 64 to 76)
Reported as:
Median · Percent change
Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 25 (Weeks 64 to 76)
Percent changeAR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 Continued
Percent Change From Baseline in Peanut-specific IgE in Participants (Continuously) Treated With Dupilumab Plus AR101 vs Placebo Plus AR101 to Visit 25 (Weeks 64 to 76)-7.2 (-84.6 to 94.7)-73.9 (-91.6 to -45.5)
Statistical analysis
  • AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued vs AR101 Maintenance Period: Dupilumab + AR101 Continued · ANCOVA · p = <0.0001 (P-value was based on treatment difference (vs. Continuously on Placebo + AR101) in percent change from baseline using rank-based ANCOVA model with baseline measurement as covariate, and stratification factors and the treatment as fixed factors.) · Difference in percentage: -68.78 · 95% CI -86.71 to -56.40Median difference and its 95% CIs were estimated with the Hodges-Lehmann method.

Adverse events

Collected over From first dose of study drug up to Week 76. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-AR101 Dosing Period: Placebo-matched Dupilumab0/50 (0%)0/50 (0%)12/50 (24%)
Pre-AR101 Dosing Period: Dupilumab0/98 (0%)0/98 (0%)23/98 (23.5%)
AR101 Up-dosing Period: Placebo + AR1010/49 (0%)0/49 (0%)34/49 (69.4%)
AR101 Up-dosing Period: Dupilumab + AR1010/96 (0%)0/96 (0%)47/96 (49%)
AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 Continued0/40 (0%)0/40 (0%)13/40 (32.5%)
AR101 Maintenance Period: Dupilumab + AR101 Continued0/42 (0%)1/42 (2.4%)17/42 (40.5%)
AR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR1010/43 (0%)0/43 (0%)15/43 (34.9%)
Most frequent serious events
Most frequent serious events
EventPre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101
AppendicitisInfections and infestations0/500/980/490/960/401/420/43
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabAR101 Up-dosing Period: Placebo + AR101AR101 Up-dosing Period: Dupilumab + AR101AR101 Maintenance Period: Placebo-matched Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101 ContinuedAR101 Maintenance Period: Dupilumab + AR101/Placebo-matched Dupilumab + AR101
Upper respiratory tract infectionInfections and infestations5/502/987/4916/961/405/420/43
VomitingGastrointestinal disorders0/502/988/495/961/402/420/43
Abdominal painGastrointestinal disorders0/501/985/499/961/404/423/43
DiarrhoeaGastrointestinal disorders0/501/985/495/960/403/421/43
CoughRespiratory, thoracic and mediastinal disorders0/501/985/494/960/401/420/43
AsthmaRespiratory, thoracic and mediastinal disorders1/500/984/492/964/400/421/43
Abdominal pain upperGastrointestinal disorders0/501/982/498/961/401/422/43
RashSkin and subcutaneous tissue disorders0/500/984/494/961/402/423/43
HeadacheNervous system disorders1/502/984/495/961/401/422/43
Rhinitis allergicRespiratory, thoracic and mediastinal disorders1/500/983/493/963/401/422/43

Baseline characteristics

Full analysis set (FAS) included all randomized participants

Age, Continuous
Age, Continuous(years)Pre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabTotal
Mean10.9 ± 3.0011.3 ± 3.1211.1 ± 3.08
Sex: Female, Male
Sex: Female, Male(Participants)Pre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabTotal
Female183856
Male326092
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabTotal
Hispanic or Latino4812
Not Hispanic or Latino4587132
Unknown or Not Reported134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pre-AR101 Dosing Period: Placebo-matched DupilumabPre-AR101 Dosing Period: DupilumabTotal
White4070110
Black or African American134
Asian71825
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander011
Other268
08

Study locations

25 sites
  • Regeneron Investigational Site
    Birmingham, Alabama 35209, United States
  • Regeneron Investigational Site
    Tucson, Arizona 85724, United States
  • Regeneron Investigational Site
    Little Rock, Arkansas 72202, United States
  • Regeneron Investigational Site
    Los Angeles, California 90027, United States
  • Regeneron Investigational Site
    Los Angeles, California 90095, United States
  • Regeneron Investigational Site
    Mission Viejo, California 92691, United States
  • Regeneron Investigational Site
    Mountain View, California 94040, United States
  • Regeneron Investigational Site
    Rolling Hills Estates, California 90274, United States
  • Regeneron Investigational Site
    Denver, Colorado 80206, United States
  • Regeneron Investigational Site
    Washington, District of Columbia 20010, United States
  • Regeneron Investigational Site
    Tampa, Florida 33612, United States
  • Regeneron Investigational Site
    Atlanta, Georgia 30329, United States
  • Regeneron Investigational Site
    Marietta, Georgia 30144, United States
  • Regeneron Investigational Site
    Chicago, Illinois 60611, United States
  • Regeneron Investigational Site
    Baltimore, Maryland 21287, United States
  • Regeneron Investigational Site
    Boston, Massachusetts 02114, United States
  • Regeneron Investigational Site
    Ann Arbor, Michigan 48106, United States
  • Regeneron Investigational Site
    Ypsilanti, Michigan 48197, United States
  • Regeneron Investigational Site
    Minneapolis, Minnesota 55402, United States
  • Regeneron Investigational Site
    Ocean Township, New Jersey 07712, United States
  • Regeneron Investigational Site
    Great Neck, New York 11021, United States
  • Regeneron Investigational Site
    New York, New York 10029, United States
  • Regeneron Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • Regeneron Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Regeneron Investigational Site
    Seattle, Washington 98115, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Oct 2020, 24 months.

Results were first posted in Feb 2024, 3 years 3 months after primary completion. A results delay was requested in Oct 2021.

Of 18 phase 2 interventional studies under Peanut Hypersensitivity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2018
First posted
Sep 25, 2018
StartActual
Oct 3, 2018
Primary completionActual
Oct 16, 2020
CompletionActual
Jul 23, 2021
Results delay requested
Oct 14, 2021
Results first posted
Feb 7, 2024
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03682770
Collaborators
Sanofi, Aimmune Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 25, 2018
Start date
Oct 3, 2018
Primary completion
Oct 16, 2020
Completion
Jul 23, 2021
Results posted
Feb 7, 2024
Last update
Feb 7, 2024

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion